SCHEMBL31689553

SCHEMBL31689553

N[C@@H](Cc1cc(NS(=O)(=O)c2ccccc2)cc(NS(=O)(=O)c2ccccc2)c1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.53
ALPI P09923 1/20 0.53
PTGS1 P23219 1/20 0.53
XIAP P98170 1/20 0.53
SLC7A5 Q01650 1/20 0.53
HTR6 P50406 5/20 0.52
HDAC1 Q13547 2/20 0.48
PPARG P37231 1/20 0.48
CYTH2 Q99418 1/20 0.48
KEAP1 Q14145 2/20 0.47
IL1RN P18510 1/20 0.47
ERAP1 Q9NZ08 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
F2 P00734 1/20 0.46
F10 P00742 1/20 0.46
FURIN P09958 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31689529 0.89 HTR6 (0.64) PKMALPIPTGS1XIAPSLC7A5
SCHEMBL31689516 0.88 ALDH1A1 (0.51) SLC7A5HDAC1MEN1KMT2AHDAC8
SCHEMBL19234913 0.87 HDAC1 (0.62) PKMALPIPTGS1XIAPSLC7A5
SCHEMBL5078465 0.87 HDAC1 (0.62) PKMALPIPTGS1XIAPSLC7A5
SCHEMBL20715878 0.87 HDAC1 (0.62) PKMALPIPTGS1XIAPSLC7A5
SCHEMBL31689460 0.83 SLC7A5 (0.49) PKMALPIPTGS1XIAPSLC7A5
SCHEMBL7359876 0.82 HTR6 (0.55) PKMALPIPTGS1XIAPSLC7A5
SCHEMBL5607322 0.80 UQCRB (0.58) PKMALPIPTGS1XIAPSLC7A5
SCHEMBL5607316 0.80 UQCRB (0.58) PKMALPIPTGS1XIAPSLC7A5
SCHEMBL31689601 0.80 SLC7A5 (0.47) PKMALPIPTGS1XIAPSLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-11-06 US disclosed
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-10-16 US disclosed
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof Maxymune Therapeutics, Inc. (US) 2025-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 PKM 841/4885ALPI 2052/4885PTGS1 1933/4885
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof SLC43A1, SLC7A1, SLC1A5 PKM 841/4885ALPI 2052/4885PTGS1 1933/4885
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 PKM 841/4885ALPI 2052/4885PTGS1 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.